Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-58 Nivolumab in Relapsed/Refractory Multiple Myeloma
jRCT2080223581Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in multiple myeloma (MM), sponsored by Ono Pharmaceutical. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080223581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223581.